Trials / Completed
CompletedNCT00212862
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,130 (actual)
- Sponsor
- Ortho Biotech Products, L.P. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe patient characteristics, treatment patterns, and clinical outcomes in adult patients with cancer who are receiving erythropoiesis-stimulating therapy (EST).
Detailed description
The Dosing and Outcomes Study of Erythropoietic Stimulating Therapies (DOSE) is a prospective, observational multicenter registry of approximately 1200 adult cancer patients receiving treatment with EST; eg, epoetin alfa or darbepoetin alfa. The planned duration of the DOSE Registry is three years. Based on initial results, the registry sponsor may elect to extend the duration of the registry.This study does not specify treatment protocols, require any particular assignment of patients to treatment protocols, or in any other way require participating physicians to alter their practice patterns. Participating physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on baseline patient characteristics, treatment patterns, and clinical outcomes. Baseline determinations will include patient demographics, tumor and treatment type, hematologic parameters, and patient reported outcomes. Data will be collected over the 16-week study period with regard to EST treatment, hematologic outcomes and patient reported outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Patients with chemotherapy induced anemia | Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline. |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2005-09-21
- Last updated
- 2014-06-30
Source: ClinicalTrials.gov record NCT00212862. Inclusion in this directory is not an endorsement.